.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Prostate Cancer: Evolving Treatment Approaches

EP. 1: Ep. 1: Initiating Therapy for CSPC

March 31st 2020

EP. 2: Ep. 2: Identifying and Monitoring Testosterone Levels in CSPC

March 31st 2020

EP. 3: Ep. 3: Addressing Cardiovascular Risk and Events in CSPC

March 31st 2020

EP. 4: Ep. 4: Currently Approved Therapies for Metastatic CSPC

March 31st 2020

EP. 5: Ep. 5: Ongoing CSPC Clinical Trials

March 31st 2020

EP. 6: Ep. 6: Identifying Nonmetastatic CRPC

March 31st 2020

EP. 7: Ep. 7: Current Treatment and Imaging Options for nmCRPC

March 31st 2020

EP. 8: Ep. 8: Selecting Optimal AR-Targeted Therapy for nmCRPC

March 31st 2020

EP. 9: Ep. 9: Neurological AEs and Quality of Life in Treating nmCRPC

March 31st 2020

EP. 10: Ep. 10: How Has the mCRPC Treatment Landscape Changed?

March 31st 2020

EP. 11: Ep. 11: Factors in Selecting Therapy for mCRPC

March 31st 2020

EP. 12: Ep. 12: What is Radium 223

March 31st 2020

EP. 13: Ep. 13: Avoiding Repeat Lines of AR-Targeted Therapy in mCRPC

March 31st 2020

EP. 14: Ep. 14: Emerging Agents in the Management of Prostate Cancer

March 31st 2020